Skip to main content

Table 2 Mean Change in BPI–Severity and BPI–Interference Items during the Extension Phase

From: Maintenance of effect of duloxetine in Chinese patients with pain due to osteoarthritis: 13-week open-label extension data

Variable

DLX_DLX

PLA_DLX

N = 166

N = 175

Baseline

Change

Baseline

Change

Average pain

3.3 (1.8)

−1.0 (1.7)***

3.7 (1.8)

−1.4 (1.6)***

Worst pain

4.2 (2.1)

−1.1 (2.0)***

4.8 (1.9)

−1.6 (1.7)***

Least pain

2.2 (1.9)

−0.9 (1.6)***

2.5 (1.9)

−1.0 (1.7)***

Right now pain

2.8 (2.1)

−1.1 (1.7)***

3.3 (2.1)

−1.4 (1.7)***

Average Interference

1.9 (1.8)

−0.6 (1.1)***

2.2 (1.7)

−0.8 (1.2)***

General activity

3.0 (2.3)

−0.9 (1.9)***

3.6 (2.2)

−1.3 (1.9)***

Mood

1.2 (2.0)

−0.4 (1.2)***

1.6 (2.1)

−0.6 (1.7)***

Walking ability

3.0 (2.2)

−0.9 (1.6)***

3.5 (2.2)

−1.3 (1.7)***

Normal work

2.6 (2.3)

−0.9 (1.8)***

3.1 (2.2)

−1.1 (1.9)***

Relations with other people

0.8 (1.8)

−0.2 (1.1)**

0.9 (1.7)

−0.3 (1.2)**

Sleep

1.3 (2.2)

−0.5 (1.7)***

1.5 (2.1)

−0.5 (1.6)***

Enjoyment of life

1.2 (2.1)

−0.5 (1.5)***

1.2 (2.0)

−0.5 (1.6)***

  1. **p < 0.01; ***p < 0.001 (within-group, 2-sided t-test). Data are shown as mean (standard deviation). Baseline is the last non-missing observation during the placebo-controlled phase. Change is the change from the last non-missing observation during the placebo-controlled phase to the last non-missing observation during the extension phase
  2. Abbreviations: BPI Brief Pain Inventory, DLX duloxetine, PLA placebo